Anthony Fauci speaks at a Feb. 7 press conference on coronavirus developments. Photo: Samuel Corum/Getty Images

A leading U.S. health official said Tuesday it's "very frustrating" that no major drug firm has yet offered to make a vaccine against the novel coronavirus that the National Institutes of Health is helping develop, STAT News reports.

Why it matters: When outbreaks of new worrisome pathogens start, governments may immediately start working on diagnostics, vaccines and treatments, but they also need a buy-in from drug companies that sometimes get burned if the outbreak suddenly peters out or the drug isn't successful.

Details: National Institute of Allergy and Infectious Diseases director Anthony Fauci said on a panel hosted by STAT and the Aspen Institute that it'd take "at least a year" before a coronavirus vaccine could become available — and that's assuming a pharmaceutical manufacturing giant were to produce the product.

  • Fauci noted that although the NIH had partnered with Moderna to develop a COVID-19 vaccine, a large manufacturer would be needed to "take on the risky venture of manufacturing the product if it is successful in human testing," according to an S&P Global report of the panel discussion.
  • "The companies that have the skill to be able to do it ... [are] going to have to stop making polio vaccines, measles vaccines, hepatitis vaccines to put your particular product in," Fauci said, per S&P Global.

The big picture: Several U.S. pharmaceutical firms have said they're working on their own vaccines against the new coronavirus, which has killed over 1,1100 people and infected more than 45,000 others — mostly in mainland China. These include Inovio, Johnson & Johnson and Novavax, according to the State Department.

What they're saying: Johnson & Johnson said Tuesday its Janssen Pharmaceutical Companies would "further expedite its investigational coronavirus vaccine program" in collaboration with HHS'' Biomedical Advanced Research and Development Authority.

  • "This partnership will ensure that vital research is made possible at rapid speed and underscores the importance of public-private partnerships to tackle the worldwide novel coronavirus epidemic," Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson, said in a statement.
  • "We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world."

Go deeper:

Go deeper

Ben Geman, author of Generate
38 mins ago - Politics & Policy

The new politics of global warming

Photo illustration: Sarah Grillo/Axios. Getty Images photos: Ethan Miller and Chip Somodevilla

The 2020 election is both very different and very familiar when it comes to the politics of global warming and the stakes of the outcome.

What's new: Democratic voters are more concerned than in prior presidential cycles, polling shows.

Bryan Walsh, author of Future
43 mins ago - Energy & Environment

Pinpointing climate change's role in extreme weather

Photo illustration: Aïda Amer/Axios. Getty Images photos: David McNew and George Rose

Climate scientists are increasingly able to use computer models to determine how climate change makes some extreme weather more likely.

Why it matters: Climate change's effects are arguably felt most directly through extreme events. Being able to directly attribute the role climate plays in natural catastrophes can help us better prepare for disasters to come, while driving home the need to tackle greenhouse gas emissions.

Amy Harder, author of Generate
48 mins ago - Energy & Environment
Column / Harder Line

Big Tech takes the climate change lead

Photo illustration: Aïda Amer/Axios. Getty Images photo: Jit Chattopadhyay/Pacific Press/LightRocket

The tech industry is playing a growing role in fighting climate change, from zero-carbon commitments to investments in startups and pushing for the use of data to encourage energy efficiency.

Why it matters: Big Tech is already dominating our economy, politics and culture. Its leadership in helping to address climate change — and reckon with its role in contributing to it — could have similarly transformative impacts.